Recommended Dose: The recommended dose is 6 mg/kg administered by intravenous infusion once every 3 weeks (Q3W) until disease progression or unacceptable toxicity.The maximum dosage for patients weighing ≥90 kg is 540 mg.

Time: The initial infusion should be administered over approximately 90 minutes. If well tolerated, subsequent infusions may be administered over 30 minutes.

Instructions for use: Reconstitute and dilute before intravenous infusion according to the approved prescribing information. Datopotamab deruxtecan-dlnk should be administered by intravenous infusion only and should not be administered as an intravenous push or bolus. Monitor patients for infusion-related reactions during and after administration. Regular monitoring of complete blood counts, pulmonary symptoms, and ocular symptoms is recommended during treatment. Dose interruption, dose reduction, or permanent discontinuation may be required depending on the severity of adverse reactions, including interstitial lung disease/pneumonitis, hematologic toxicity, stomatitis, and other treatment-related toxicities.

Interaction: No formal clinical drug interaction studies have been conducted with datopotamab deruxtecan-dlnk. The antibody-drug conjugate is primarily eliminated through intracellular catabolism, and clinically significant CYP450-mediated interactions are not expected. Caution should be exercised when used concomitantly with drugs that may increase the risk of overlapping toxicities.

Side effects: Common adverse reactions include stomatitis, nausea, alopecia, fatigue, decreased appetite, anemia, neutropenia, lymphopenia, diarrhea, and vomiting. Serious adverse reactions may include interstitial lung disease/pneumonitis, severe infections, hematologic toxicities, and infusion-related reactions. Ocular toxicity may occur and appropriate monitoring and management should be considered.